Deep Genomics logo

Deep Genomics

3 Followers

About

Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.

No jobs yet!

Team announcement

Deep Genomics named Amanda Kay Chief Business Officer

Deep Genomics named Amanda Kay Chief Business Officer

AI therapeutics company Deep Genomics has announced Amanda Kay has been hired in the newly created position of Chief Business Officer. Dr. Kay will be responsible for the company’s expansion of its partnership strategy, as well as leading its corporate strategy. “Amanda joins at a critical inflection point for Deep Genomics. The evolution of our AI Workbench has allowed us to rapidly identify genetically defined targets and design compounds with high therapeutic potential,” said Deep Genomics Founder and Chief Executive Officer Brendan Frey. “We are now advancing a broad pipeline of pre-clinical programs. However, the number of programs and our ability to advance even more programs far exceeds our clinical development capacity. To address the needs of patients, Amanda will oversee a massive expansion of our partnership strategy. This will enable us to tap into the clinical development and commercialization capabilities of other leading pharmaceutical companies.” Dr. Kay is an experienced biopharmaceutical executive with expertise in strategy development, operating plan implementation, business development, commercialization, financial planning and analysis, and R&D operations. She comes to Deep Genomics from Synlogic, where she was a member of the executive team as Vice President of Corporate Development. “I’m excited to work with Brendan and the team to deliver on the promise of our platform and bring new medicines to patients,” said Dr. Kay. “I’ve been wondering about what AI means for drug development for some time; there’s a lot of talk out there that sounds like magic. When I met the Deep Genomics team and heard about their AI Workbench, the advantages of AI became real for me. What they are doing is very tangible and the benefits of their AI for different aspects of drug development can, and have, been measured. I am certain that the ability to quickly predict and develop high-potential drug candidates will make Deep Genomics an important collaboration partner." As well as the appointment of Dr. Kay, Deep Genomics has also announced that Navitor Pharmaceuticals CEO, Dr. Thomas E. Hughes, has been appointed to its board of directors.

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.